Contrasting Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Perspective Therapeutics (NYSE:CATX)

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Perspective Therapeutics (NYSE:CATX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.

Risk & Volatility

Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.

Earnings & Valuation

This table compares Health Sciences Acquisitions Co. 2 and Perspective Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380,000.00	N/A	N/A
Perspective Therapeutics	$1.43 million	150.77	-$46.51 million	N/A	N/A

Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than Perspective Therapeutics.

Insider & Institutional Ownership

89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are held by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Comparatively, 3.5% of Perspective Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Health Sciences Acquisitions Co. 2 and Perspective Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%

Analyst Recommendations

This is a breakdown of recent recommendations for Health Sciences Acquisitions Co. 2 and Perspective Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Sciences Acquisitions Co. 2	0	0	0	0	0.00
Perspective Therapeutics	0	1	8	0	2.89

Perspective Therapeutics has a consensus target price of $15.14, suggesting a potential upside of 374.70%. Given Perspective Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Perspective Therapeutics is more favorable than Health Sciences Acquisitions Co. 2.

Summary

Health Sciences Acquisitions Co. 2 beats Perspective Therapeutics on 6 of the 11 factors compared between the two stocks.

About Health Sciences Acquisitions Co. 2

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.